Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment.

Ekali LG, Johnstone LK, Echouffo-Tcheugui JB, Kouanfack C, Dehayem MY, Fezeu L, Nouthe B, Hayes L, Unwin NC, Sobngwi E.

Diabetes Metab. 2013 Feb;39(1):71-7. doi: 10.1016/j.diabet.2012.08.012. Epub 2012 Nov 13.

PMID:
23153435
3.

Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

Viganò A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, Cerini C, Giacomet V, Zuccotti GV, Bedogni G.

Clin Drug Investig. 2009;29(2):101-9. doi: 10.2165/0044011-200929020-00004.

PMID:
19133705
4.

Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT, Carpenter CC.

J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):107-13.

PMID:
10360801
5.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
6.

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.

7.

Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Koppel K, Bratt G, Schulman S, Bylund H, Sandström E.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):441-9.

PMID:
11981359
8.
9.

Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.

Muhammad S, Sani MU, Okeahialam BN.

Ann Afr Med. 2013 Jan-Mar;12(1):24-8. doi: 10.4103/1596-3519.108246.

10.
11.

Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy.

Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, Choi JY, Song YG, Lee HC, Kim JM.

Metabolism. 2009 Nov;58(11):1523-9. doi: 10.1016/j.metabol.2009.04.021. Epub 2009 Jun 18.

PMID:
19501863
13.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
14.

Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women.

Danoff A, Shi Q, Justman J, Mulligan K, Hessol N, Robison E, Lu D, Williams T, Wichienkuer P, Anastos K; Women's Interagency HIV Study (WIHS)..

J Acquir Immune Defic Syndr. 2005 May 1;39(1):55-62.

PMID:
15851914
15.

Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.

Abebe M, Kinde S, Belay G, Gebreegziabxier A, Challa F, Gebeyehu T, Nigussie P, Tegbaru B.

BMC Res Notes. 2014 Jun 21;7:380. doi: 10.1186/1756-0500-7-380.

16.

Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.

Blass SC, Ellinger S, Vogel M, Ingiliz P, Spengler U, Stehle P, von Ruecker A, Rockstroh JK.

Eur J Med Res. 2008 May 26;13(5):209-14.

PMID:
18559303
17.

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

Hatano H, Miller KD, Yoder CP, Yanovski JA, Sebring NG, Jones EC, Davey RT Jr.

AIDS. 2000 Sep 8;14(13):1935-42.

PMID:
10997397
18.
19.

Prevalence of dyslipidemia and dysglycaemia in HIV infected patients.

Manuthu EM, Joshi MD, Lule GN, Karari E.

East Afr Med J. 2008 Jan;85(1):10-7.

PMID:
18543521
20.

Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.

Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V.

J Pediatr Endocrinol Metab. 2014 May;27(5-6):403-12. doi: 10.1515/jpem-2013-0253.

PMID:
24259240

Supplemental Content

Support Center